AbbVie Director Edward Rapp Receives Routine Stock Equivalent Units
AbbVie Inc.
Subscribe to track ABBV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# SEC Form 4: AbbVie Inc. (ABBV)
**Insider:** RAPP EDWARD J (Director)
**Transaction Date:** September 30, 2026
**Filing Date:** October 2, 2026
### Transaction Summary
* **Type:** Grant / Acquisition (Code A)
* **Security:** Stock Equivalent Units
* **Shares:** 129
* **Price:** $261.59
* **Total Value:** $33,745.11
* **Ending Balance:** 29,568 units
### Significance
* **Rating:** Low
* **Notes:** Routine quarterly director compensation credited into stock equivalent units under a director grantor trust.
Comprehensive Analysis
Transaction Overview
On October 2, 2026, AbbVie Inc. (NYSE: ABBV) director Edward J. Rapp reported an acquisition of 129 Stock Equivalent Units on September 30, 2026, priced at $261.59 per unit, representing a total transaction value of approximately $33,745.11.
Following this transaction, Mr. Rapp directly holds 29,568 stock equivalent units.
Context and Footnote Details
- Grant Mechanism: According to Footnote 1, the transaction reflects director fees credited to a stock equivalent unit account under the director's grantor trust. These units are distributed over a period equal to the director's years of board service, typically starting at age 65 or upon retirement from the board.
- Reinvestment: Footnote 2 clarifies that the cumulative balance also includes stock equivalent units acquired under a dividend reinvestment feature.
Market and Trading Assessment
This transaction represents routine, equity-based board compensation paid in lieu of cash director fees. It does not reflect an open-market purchase or discretionary insider sentiment, which translates to Low market/trading significance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.